FDA Advisers Consider Novavax COVID-19 Vaccine This Week
An FDA panel will consider Novavax's COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.
Source: medscape.com